Gutenberg Open Science: Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7549

Full metadata record

DC Field	Value	Language
dc.contributor.author	Oezkur, Mehmet	-
dc.contributor.author	Reda, Sara	-
dc.contributor.author	Rühl, Heiko	-
dc.contributor.author	Theuerkauf, Nils	-
dc.contributor.author	Kreyer, Stefan	-
dc.contributor.author	Duerr, Georg Daniel	-
dc.contributor.author	Charitos, Efstratios	-
dc.contributor.author	Silaschi, Miriam	-
dc.contributor.author	Medina, Marta	-
dc.contributor.author	Zimmer, Sebastian	-
dc.contributor.author	Putensen, Christian	-
dc.contributor.author	Treede, Hendrik	-
dc.date.accessioned	2022-08-11T10:05:44Z	-
dc.date.available	2022-08-11T10:05:44Z	-
dc.date.issued	2021	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/7563	-
dc.description.abstract	Axial flow pumps are standard treatment in cases of cardiogenic shock and high-risk interventions in cardiology and cardiac surgery, although the optimal anticoagulation strategy remains unclear. We evaluated whether laboratory findings could predict bleeding complications and acquired von Willebrand syndrome (avWS) among patients who were treated using axial flow pumps. We retrospectively evaluated 60 consecutive patients who received Impella devices (Impella RP: n = 20, Impella CP/5.0: n = 40; Abiomed Inc., Danvers, USA) between January 2019 and December 2020. Thirty-two patients (53.3%) experienced major or fatal bleeding complications (Bleeding Academic Research Consortium score of > 3) despite intravenous heparin being used to maintain normal activated partial thromboplastin times (40–50 s). Extensive testing was performed for 28 patients with bleeding complications (87.5%). Relative to patients with left ventricular support, patients with right ventricular support were less likely to develop avWS (87.5% vs. 58.8%, p = 0.035). Bleeding was significantly associated with avWS (odds ratio [OR]: 20.8, 95% confidence interval [CI]: 3.3–128.5; p = 0.001) and treatment duration (OR: 1.3, 95% CI 1.09–1.55; p = 0.003). Patients with avWS had longer Impella treatment than patients without avWS (2 days [1–4.7 days] vs. 7.3 days [3.2–13.0 days]). Bleeding complications during Impella support were associated with avWS in our cohort, while aPTT monitoring was not sufficient to prevent bleeding complications. A more targeted anticoagulation monitoring might be needed for patients who receive Impella devices.	en_GB
dc.language.iso	eng	de
dc.rights	CC BY	*
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-7549	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Scientific reports	de
jgu.journal.volume	11	de
jgu.pages.alternative	23722	de
jgu.publisher.year	2021	-
jgu.publisher.name	Macmillan Publishers Limited, part of Springer Nature	de
jgu.publisher.place	London	de
jgu.publisher.issn	2045-2322	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1038/s41598-021-02833-8	de
jgu.organisation.ror	https://ror.org/023b0x485	-
Appears in collections:	JGU-Publikationen

Files in This Item:

	File	Description	Size	Format
	role_of_acquired_von_willebra-20220811115355315.pdf		989.15 kB	Adobe PDF	View/Open

Show simple item record